Proactive Investors - Run By Investors For Investors

LeanLife Health names Jason Tong as new finance chief

Tong is currently the finance chief at ExGen Resources and is a senior advisor to several companies
A boardroom
Tong was appointed as chief financial officer following the resignation of Casey Forward

LeanLife Health Inc (CSE:LLP) unveiled some board changes, including the appointment of experienced executive Jason Tong as the group's new finance chief.

He was appointed as chief financial officer following the resignation on January 9 of Casey Forward who stepped down due to health reasons.

READ: LeanLife Health to benefit from Canada’s sweeping new food safety rules

Tong is currently the finance chief at ExGen Resources and is a senior advisor to several high- growth companies.

He has served in senior management roles for a number of public and private companies and was previously the chief financial officer of Pathway Capital Ltd, a venture capital group with a portfolio of early-stage ventures with market caps ranging from $5 million to $100 million.

He was also CFO at Turnberry Resources Ltd from February 2012 until it was acquired in April 2014.

Also in the statement, LeanLife said shareholders had voted in favour of all resolutions at its AGM on January 4 this year.

Vancouver-based LeanLife has developed a patented process to isolate omega 3 fatty acids from flax (linen) seeds — one of the richest plant sources of this essential fatty acid.

Contact Giles at [email protected]

View full LLP profile View Profile

LeanLife Health Timeline

Newswire
February 07 2019

Related Articles

parsortix
February 01 2019
The cancer detection device is on track to finish a key clinical study in the first quarter of 2019, but in the meantime, it has shown promise in detecting abnormalities in unborn children
scientist in lab
December 18 2018
VAL401 is ValiRx’s most advanced compound, with earlier trial results suggesting it can improve quality of life and chances of survival of lung cancer patients
Antigens
November 29 2018
The deal with New England Biolabs, signed in October, is expected to secure six-figure royalty sums as soon as next year
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use